No products in the basket.
[button : interested : interested : CM177]
Autism spectrum disorders (ASDs) are neurodevelopmental disorders characterized by difficulties in social interaction, communication problems, and a tendency to engage in repetitive behaviors.
However, symptoms and their severity vary considerably in these three key areas. Collectively, they can lead to relatively mild challenges to more severe symptoms, such as when repetitive behaviours and lack of spoken language interfere with everyday life. It was quite exciting when Dr. Michael Chez, a neuroscientist, published the results of treatment for autistic disorders (autism and Asperger’s Syndrome). Since 2001, he has treated nearly 1,000 autistic children with carnosine. Based on this study, Dr. Chez suggested that carnosine may improve neurological function. He found that in 80% to 90% of cases, the condition improved significantly after only 8 weeks of treatment (Chez et al, 2002). Dr Chez suggests that carnosine acts in the frontal parts of the brain, where its effects combine with those of neurotransmitters acting in the deep parts of the brain. The excellent results of this treatment have been confirmed by parents of autistic children after only one week of treatment.
Improvements were observed in communication, behaviour and social contact. The treatment of dyslexic children by Doctor Chaz also showed improvement, especially in reading and attention levels. In addition to reports of treatment of 1,000 autistic children, Dr. Chez conducted double-blind research with 31 autistic children with similar results. The double-blind study meant that it was not known which children received the supplement and which the placebo. The children who received the placebo made no gains. They were given 800 mg of pure L-carnosine daily and no side effects were observed (Chez et al, 2002).
Administration of carnosine resulted in demonstrable improvements in autistic behavior as well as an increase in language comprehension that reached statistical significance.
Although the mechanism of action of this dipeptide is not well understood, it is thought to act by modulating neurotransmission and influencing the transport of zinc and copper metal ions in the entorhinal cortex. L-carnosine may enhance neurological function or act as a neuroprotective peptide.
– Sleep deprivation is a common finding in autistic children. The following clinical study investigated the effects of L-carnosine on sleep disturbances in autistic children. The study enrolled 43 children (aged 4-16 years) who were followed via standardized questionnaires for 2 months. After this period, the results were compared with the placebo group and it was concluded that L-carnosine is effective in improving sleep disorders, especially sleep duration and parasomnias (Mehrazad-Saber, Kheirouri, & Noorazar, 2018).
Risperidone is one of the limited approved medications for the treatment of hyperactivity, irritability, and aggression in children with autism spectrum disorders (ASD). Researchers from Tehran (Iran) came up with the idea to investigate whether adding L-carnosine to risperidone treatment can improve the behavior of children with PAS. The participants of the study – 70 children with PAS (4-12 years old) received either risperidone + placebo or risperidone + L-carnosine, and their condition was assessed using a standardized ABC-C scale. After 10 weeks, the results of both study groups were compared and showed that L-carnosine in addition to risperidonenu can improve hyperactivity symptoms in PAS (Hajizadeh-Zaker, Ghajar, Mesgarpour, Afarideh, Mohammadi & Akhondzadeh, 2018).
– Autism spectrum disorders are often associated with metabolic disorders. It has been shown that children with PAS typically have imbalanced gut microbiota and altered metabolites, including carnosesnu, which is significantly reduced in this disorder (Ming, Stein, Barnes, Rhodes & Guo, 2012; Zaki, Abdel-Al & Al-Sawi, 2017 )
– Markers of oxidative stress are elevated in PAS, suggesting impaired mitochondrial functioning. Carnosine is a potent antioxidant that significantly improves behavior in PAS (McGinnis, 2004).
– The presence of Clostridium bacteria in the gut of children with PAS is well documented. Clostridium difficile produces propionic acid (PA), which causes serious neurological problems including social impairment, repetitive behaviors, and obsessive-compulsive behaviors. This study demonstrates the superior effect of carnosine, which induces 300% and 350% recovery in PA intoxicated brains (El-Ansary, Shaker, El-Gezeery & Al-Ayadhi, 2013). – Similarly, this study hypothesized that propionic acid (PA) interferes with neurotransmitters in the brain of PAS. When carnosine was co-administered with PA, it tended to restore altered neurotransmitter levels to near normal levels (El-Ansary, Shaker, Siddiqi & Al-Ayadhi, 2013).
– Autism often co-occurs with epilepsy and seizures. L-carnosine appears to be well tolerated and has the potential to improve both PAS symptoms and seizures, so it may be a promising therapy for individuals with PAS and seizures (Frye et al, 2013).
– Researchers have hypothesized that immunological function is altered in PAS. L-carnosine may be a potential and promising agent in PAS, modulating immune function. The beneficial effects of L-carnosine on PAS symptoms can be attributed to its immunomodulatory, antioxidant, glutamatergic, and NMDA- and GABA-modulating activities (Marchezan, dos Santos, Deckmann & dos Santos Riesgo, 2018). References Chez, M. G., Buchanan, C. P., Aimonovitch, M. C., Becker, M., Schaefer, K., Black, C., & Komen, J. (2002). A double-blind, placebo-controlled study of L-carnosine supplementation in children with autism spectrum disorders. Journal of Child Neurology, 17(11), 833-837.
https://doi.org/10.1177/08830738020170111501 El-Ansary, A., Shaker, G. H., El-Gezeery, A. R., & Al-Ayadhi, L. (2013). Neurotoxic effect of intestinal bacterial imbalance induced by clindamycin and orally administered propionic acid on DNA damage assessed by the comet assay: Protective power of carnosine and carnitine. Enteric Pathogens, 5(1), 9. El-Ansary, A., Shaker, G., Siddiqi, N. J., & Al-Ayadhi, L. Y. (2013). Possible ameliorating effects of antioxidants on propionic acid/clindamycin-induced neurotoxicity in Syrian hamsters. Enteric Pathogens, 5(1), 32. Frye, R. E., Rossignol, D., Casanova, M. F., Martin, V., Brown, G., Edelson, S. M., … & Hardy, P. (2013). A review of traditional and new treatments for seizures in autism spectrum disorder: findings from a systematic review and expert panel. Frontiers in Public Health, 1, 31. Hajizadeh-Zaker, R., Ghajar, A., Mesgarpour, B., Afarideh, M., Mohammadi, M. R., & Akhondzadeh, S. (2018). l-Carnosine as adjunctive therapy to risperidone in children with autistic disorder: A randomized, double-blind, placebo-controlled trial. Journal of child and adolescent psychopharmacology, 28(1), 74-81. https://doi.org/10.1089/cap.2017.0026 Marchezan, J., dos Santos, E. G. A. W., Deckmann, I., & dos Santos Riesgo, R. (2018). Immunological dysfunction in autism spectrum disorder: A potential target for therapy. Neuroimmunomodulation, 25(5-6), 300-319. McGinnis, W. R. (2004). Oxidative stress in autism. Alternative therapies in health and medicine, 10(6), 22-92. Mehrazad-Saber, Z., Kheirouri, S., & Noorazar, S. G. (2018). Effects of l-carnosine supplementation on sleep disturbances and illness severity in autistic children: a randomized, controlled clinical trial. Basic and Clinical Pharmacology and Toxicology, 123(1), 72-77. Ming, X., Stein, T. P., Barnes, V., Rhodes, N., & Guo, L. (2012). Metabolic disturbances in autism spectrum disorders: a metabolomic study. Journal of proteome research, 11(12), 5856-5862. https://doi.org/10.1021/pr300910n Zaki, M. M., Abdel-Al, H., & Al-Sawi, M. (2017).
https:// www.carnomed.sk/produkty/karnozin-extra.htm
https:// www.carnomed.sk/produkty/karnozin-extra-pure-and-strong.htm
https:// www.carnomed.sk/produkty/karnozin-extra-60.htm
